펩타이드 치료제 시장 : 펩타이드 유형, 합성 기술, 투여 경로, 용도, 최종사용자별 - 시장 예측(2026-2032년)

The Peptide Therapeutics Market is projected to grow by USD 228.97 billion at a CAGR of 7.44% by 2032.

Peptide therapeutics have moved from a specialized drug class into a strategic growth engine for metabolic disease, oncology, endocrinology, rare diseases, and infectious disease research. Their clinical value is supported by established pharmacology: peptides can bind targets with high specificity, offer predictable receptor-mediated activity, and bridge the therapeutic gap between small molecules and biologics.

Commercial and clinical momentum is being reinforced by the global adoption of GLP-1 receptor agonists, continued use of insulin analogs, advances in peptide receptor radionuclide therapy, and expanding pipelines in oral, long-acting, and cell-penetrating peptide formats. For industry leaders, the peptide therapeutics market is increasingly defined by innovation in peptide synthesis, formulation science, drug delivery, analytical characterization, and scalable manufacturing quality.

Transformative Shifts in the Peptide Therapeutics Landscape

The peptide therapeutics landscape is being reshaped by three forces: next-generation delivery systems, manufacturing modernization, and therapeutic expansion beyond traditional endocrine indications. Long-acting injectables, depot formulations, lipidation, cyclization, permeation enhancers, and nanoparticle-enabled delivery are improving dosing convenience, stability, and patient adherence.

At the same time, solid-phase peptide synthesis, liquid-phase hybrid approaches, greener solvents, continuous manufacturing concepts, high-resolution analytics, and advanced purification technologies are improving scalability and product consistency. The competitive frontier is also shifting toward multi-receptor agonists, peptide-drug conjugates, targeted radioligands, antimicrobial peptides, and peptides designed for intracellular signaling pathways or protein-protein interaction targets.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating peptide therapeutics by improving sequence design, structure prediction, target validation, toxicity screening, and developability assessment. AI-enabled models can help prioritize peptide candidates with stronger binding affinity, improved proteolytic stability, lower immunogenicity risk, and more favorable pharmacokinetic profiles before costly wet-lab testing.

The most important cumulative impact is speed and selectivity across discovery and development. AI, machine learning, and generative design are reducing discovery cycles while supporting formulation screening, synthetic route optimization, impurity prediction, and clinical trial stratification. However, responsible adoption depends on high-quality datasets, validated models, regulatory transparency, data governance, and expert human review to ensure reproducibility and patient safety.

Key Regional Insights

North America remains a leading region for peptide therapeutics due to strong biopharmaceutical R&D, established FDA regulatory experience, venture financing, academic translation, and high uptake of metabolic, diabetes, obesity, and oncology therapies. Europe benefits from mature clinical research networks, EMA oversight, advanced GMP manufacturing capabilities, and strong activity across Germany, France, Italy, Spain, and the United Kingdom, supporting both innovative peptide drug development and high-quality production standards.

Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, and Australia invest in biosciences, contract development and manufacturing, clinical trial capacity, and advanced bioprocessing infrastructure. Latin America is gaining relevance through Brazil and Mexico as access to diabetes, obesity, and specialty care improves, while the Middle East is strengthening tertiary care, precision medicine programs, and hospital-based specialty treatment. Africa presents long-term demand linked to rising noncommunicable disease burden, infectious disease needs, and healthcare access initiatives, although affordability, cold-chain infrastructure, and regulatory capacity remain important adoption factors.

Key Group Insights

Within ASEAN, expanding healthcare coverage, medical tourism, regional manufacturing, and growing clinical research participation are creating demand for affordable peptide medicines and development partnerships. GCC markets are prioritizing specialty care, diabetes management, obesity treatment, and advanced hospital systems, making peptide-based metabolic and endocrine therapies particularly relevant to public health strategies.

The European Union remains influential through centralized regulatory pathways, research funding, pharmacovigilance standards, and quality frameworks that shape global peptide manufacturing. BRICS countries are important for scale, cost-efficient production, large patient populations, and high disease burden, particularly in diabetes, oncology, and cardiovascular-metabolic disorders. G7 markets lead premium innovation, reimbursement influence, and advanced clinical adoption, while NATO-aligned countries increasingly emphasize resilient pharmaceutical supply chains, biomedical preparedness, and secure access to critical medicines.

Key Country Insights

The United States leads peptide therapeutics innovation through FDA approvals, academic-biotech translation, advanced clinical trial infrastructure, and strong demand for GLP-1, insulin analog, oncology, and rare disease therapies. Canada supports clinical research, specialty access, and biologics-focused regulatory capabilities, while Mexico and Brazil are important Latin American markets for diabetes treatment expansion, local partnerships, and broader access to chronic disease therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced healthcare systems, reimbursement frameworks, hospital networks, and strong clinical trial activity, while Russia remains a large pharmaceutical market with localization and access considerations. China and India are scaling peptide manufacturing, active pharmaceutical ingredient capacity, and R&D programs; Japan emphasizes high-quality innovation, aging-related therapeutic demand, and stringent regulatory science; South Korea is advancing biopharma platforms and precision medicine capabilities; and Australia is recognized for early-phase clinical research strength, regulatory efficiency, and academic clinical trial networks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated peptide design, scalable manufacturing, and patient-centered delivery. Investments in long-acting formulations, oral peptide technologies, cold-chain optimization, autoinjectors, implantable or depot systems, and device-enabled administration can improve adherence, access, and clinical utility.

Organizations should strengthen AI-enabled discovery, secure high-purity raw material supply, diversify CDMO partnerships, and build regulatory evidence early around safety, immunogenicity, stability, impurities, bioanalytical performance, and comparability. Commercial teams should align access strategies with real-world evidence and outcomes data, especially in obesity, diabetes, oncology, and rare diseases where payer scrutiny, adherence evidence, and long-term safety monitoring are increasingly important.

Research Methodology

This executive summary is developed using a structured secondary research framework aligned with professional market intelligence practices. The analysis synthesizes publicly available regulatory information, clinical development trends, pharmaceutical manufacturing practices, peer-reviewed scientific literature, patent and pipeline indicators, healthcare policy updates, and macro-level healthcare indicators.

Insights are validated through triangulation across therapeutic area adoption, regional healthcare infrastructure, regulatory activity, drug development trends, manufacturing dynamics, and supply chain considerations. The methodology emphasizes data integrity, source reliability, market relevance, and practical decision support while avoiding unsupported projections, unverified claims, market estimation, market sizing, market share, or forecasting.

Conclusion

Peptide therapeutics are entering a high-value phase defined by clinical specificity, improved delivery, scalable synthesis, and expanding use across chronic and specialty diseases. The field is no longer limited to injectable endocrine drugs; it now includes multi-functional peptides, targeted radioligands, antimicrobial candidates, peptide-drug conjugates, and precision-targeted modalities.

Organizations that combine AI-enabled discovery, robust manufacturing, regulatory discipline, quality-by-design principles, and access-focused commercialization will be best positioned to lead. As demand rises across established and emerging healthcare systems, peptide therapeutics will remain a critical pillar of next-generation pharmaceutical innovation and precision medicine.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Peptide Therapeutics Market, by Peptide Type

• 7.1. Native Peptides
  • 7.1.1. Hormonal Peptides
  • 7.1.2. Neuropeptides
• 7.2. Modified Peptides
  • 7.2.1. Cyclized Peptides
  • 7.2.2. PEGylated Peptides
  • 7.2.3. Lipidated Peptides
• 7.3. Functional Peptides
  • 7.3.1. Antimicrobial Peptides
  • 7.3.2. Cell Penetrating Peptides

8. Peptide Therapeutics Market, by Synthesis Technology

• 8.1. Biological Synthesis
• 8.2. Chemical Synthesis
  • 8.2.1. Solid Phase Peptide Synthesis
  • 8.2.2. Liquid Phase Peptide Synthesis

9. Peptide Therapeutics Market, by Route Of Administration

• 9.1. Parenteral
  • 9.1.1. Intramuscular
  • 9.1.2. Intravenous
  • 9.1.3. Subcutaneous
• 9.2. Non Parenteral
  • 9.2.1. Oral
  • 9.2.2. Nasal
  • 9.2.3. Pulmonary
  • 9.2.4. Transdermal

10. Peptide Therapeutics Market, by Application

• 10.1. Cardiovascular Diseases
  • 10.1.1. Heart Failure
  • 10.1.2. Hypertension
• 10.2. Infectious Diseases
  • 10.2.1. Bacterial Infections
  • 10.2.2. Viral Infections
• 10.3. Metabolic Disorders
  • 10.3.1. Diabetes
  • 10.3.2. Obesity
  • 10.3.3. Endocrine Disorders
• 10.4. Oncology
  • 10.4.1. Breast Cancer
  • 10.4.2. Lung Cancer
  • 10.4.3. Melanoma

11. Peptide Therapeutics Market, by End User

• 11.1. Clinics
• 11.2. Hospitals
• 11.3. Research Institutes

12. Peptide Therapeutics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Peptide Therapeutics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Peptide Therapeutics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AmbioPharm Inc.
• 16.2. Amgen Inc.
• 16.3. AstraZeneca PLC
• 16.4. Aurigene Pharmaceutical Services Limited
• 16.5. Bachem Holding AG
• 16.6. Bicycle Therapeutics plc
• 16.7. Bristol-Myers Squibb Company
• 16.8. CordenPharma International GmbH
• 16.9. CSBio Inc.
• 16.10. Cybrexa Therapeutics, Inc.
• 16.11. Eli Lilly and Company
• 16.12. Ferring Pharmaceuticals A/S
• 16.13. GlaxoSmithKline PLC
• 16.14. Ipsen S.A.
• 16.15. Ironwood Pharmaceuticals, Inc.
• 16.16. Mainline Biosciences LLC
• 16.17. Novartis AG
• 16.18. Novo Nordisk A/S
• 16.19. Oncopeptides AB
• 16.20. Peptech Biosciences Ltd.
• 16.21. Peptide Institute, Inc.
• 16.22. PeptiDream Inc.
• 16.23. PolyPeptide Group AG
• 16.24. Protagonist Therapeutics, Inc.
• 16.25. Sanofi S.A.
• 16.26. SELLAS Life Sciences Group, Inc.
• 16.27. Takeda Pharmaceutical Company Limited
• 16.28. Teva Pharmaceutical Industries Ltd
• 16.29. Zealand Pharma A/S